Contact Us
News and events

Press Releases

Newsletter signup
Year
Modality
Year
    Modality

      32 Antibodies and Bispecifics

      Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform

      33 TCR Mimics

      Ypsilon Receives $2.7 Million Non-Dilutive Grant to Advance Next-Generation TCRm Antibodies

      32 Antibodies and Bispecifics

      Alloy Therapeutics Announces New Licensing Model for ATX-Gx™ Antibody Discovery Platform and Launches mAbForge™ High-Throughput Screening Service

      32 Antibodies and Bispecifics

      Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi

      32 Antibodies and Bispecifics

      Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform

      32 Antibodies and Bispecifics

      Alloy Therapeutics Announces Institutional License Agreement with Scripps Research for its ATX-Gx™ Platform for Fully Human Antibody Discovery

      32 Antibodies and Bispecifics

      Alloy Therapeutics Announces Platform License Agreement with Lilly

      32 Antibodies and Bispecifics

      Cantai Therapeutics is Co-Founded by Agent Capital and 82VS to Advance Next-Generation Bispecific Antibodies for Autoimmune Diseases

      32 Antibodies and Bispecifics

      Alloy Therapeutics and Wheeler Bio Announce Preferred Service Offering for Alloy Partners to Accelerate the Translation from Discovery to CMC

      32 Antibodies and Bispecifics

      Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation

      33 TCR Mimics

      High Efficiency CAR Discovery Screening

      32 Antibodies and Bispecifics

      Alloy Therapeutics Expands Executive Team to Strengthen Therapeutic Discovery and Innovation for Its Partners

      34 Genetic Medicines

      Alloy Therapeutics Launches Proprietary AntiClastic™ Antisense Oligonucleotide Platform to Make Potent Genetic Medicine

      32 Antibodies and Bispecifics

      Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents
      Alloy Therapeutics Unveils 2023 Innovation Roadmap Across Antibodies, TCRs, Bispecifics, and Genetic Medicines

      32 Antibodies and Bispecifics

      Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology

      32 Antibodies and Bispecifics

      34 Genetic Medicines

      Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities
      Alloy Therapeutics Hires People Executive Trier Bryant as President of Venture Studio, 82VS

      34 Genetic Medicines

      Alloy Therapeutics Ecosystem Offerings Go Intracellular Through Collaboration with Sudhir Agrawal in Genetic Medicines

      32 Antibodies and Bispecifics

      Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning

      32 Antibodies and Bispecifics

      34 Genetic Medicines

      Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering

      32 Antibodies and Bispecifics

      Alloy Therapeutics and Echo Investment Capital Create Wheeler Bio to Accelerate the Development of New Antibody Therapeutics

      32 Antibodies and Bispecifics

      Vernal Biosciences Launches to Democratize Access to High Quality mRNA Manufacturing

      32 Antibodies and Bispecifics

      Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases
      Alloy Therapeutics Raises $75 Million in Series C Financing to Advance Collaborative Biotechnology Ecosystem

      32 Antibodies and Bispecifics

      Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic Diseases

      Resources

      • Technical Notes
      Protected: High Velocity Therapeutic Antibody Discovery
      Learn more
      • Technical Notes
      Highly Specific anti-WT1/HLA-A2 TCRm Antibodies
      Learn more
      • Press Releases
      Alloy Therapeutics Establishes Multi-Year Collaboration with Pfizer to Develop New Antibody Discovery Platform
      Learn more
      • Webinars
      Daedamab High Velocity Antibody Discovery
      Learn more
      • Press Releases
      Alloy Therapeutics Announces New Licensing Model for ATX-Gx™ Antibody Discovery Platform and Launches mAbForge™ High-Throughput Screening Service
      Learn more
      • Press Releases
      Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi
      Learn more
      • Webinars
      Discovering Antibodies in Months
      Learn more
      • Technical Notes
      Approaches to Binder Recovery Following Immunization Campaigns in Mouse Models
      Learn more
      • Technical Notes
      Harnessing the Potential of Human Lambda Light Chains in Antibody Discovery Campaigns
      Learn more
      • Technical Notes
      Targeting GPCRs With DeepImmune™
      Learn more
      Contact Us

      Democratizing access to foundational biologics discovery technologies & services.

      Contact

      @alloy-therapeutics-inc

      info@alloytx.com

      275 Second Ave, Suite 200, Waltham, MA 02451

      Modalities

      Ecosystem

      Company

      Insights

      © 2025 Alloy Therapeutics, Inc. All Rights Reserved. 

      Privacy Policy | Terms & Conditions

      Signup for Alloy Therapeutics newsletter updates

      Name